Total Payments
$6,249
2022 Payments
$2,454
Companies
2
Transactions
50
Payment Breakdown by Category
Research$5,000 (80.0%)
Travel$774.13 (12.4%)
Food & Beverage$475.45 (7.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,000 | 39 | 80.0% |
| Travel and Lodging | $774.13 | 5 | 12.4% |
| Food and Beverage | $475.45 | 6 | 7.6% |
Payments by Type
Research
$5,000
39 transactions
General
$1,250
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $5,000 | 39 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,250 | 11 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $2,454 | 12 | GlaxoSmithKline, LLC. ($2,454) |
| 2020 | $1,300 | 14 | GlaxoSmithKline, LLC. ($1,300) |
| 2018 | $1,246 | 13 | GlaxoSmithKline, LLC. ($1,246) |
| 2017 | $1,250 | 11 | Novartis Pharmaceuticals Corporation ($1,250) |
All Payment Transactions
50 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/17/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $115.50 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 08/17/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $115.01 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 08/17/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $32.03 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 08/17/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $10.80 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 08/17/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $5.89 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 08/17/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $3.19 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 07/14/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $1,394.75 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 07/14/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $266.26 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 07/14/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $259.62 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 07/14/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $106.50 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 07/14/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $78.59 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 07/14/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $65.84 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: IMMUNOLOGY | ||||||
| 01/22/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | Cash or cash equivalent | $89.13 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $377.06 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $202.68 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $160.53 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $93.64 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $85.27 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $72.66 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $36.54 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $33.75 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $33.75 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $32.79 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $30.74 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
| 01/07/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | — | In-kind items and services | $27.44 | Research |
| Study: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT • Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $3,754 | 26 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST | GlaxoSmithKline, LLC. | $1,246 | 13 |
About Dr. John Trimble, MD
Dr. John Trimble, MD is a Otolaryngology healthcare provider based in Acworth, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457416570.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Trimble, MD has received a total of $6,249 in payments from pharmaceutical and medical device companies, with $2,454 received in 2022. These payments were reported across 50 transactions from 2 companies. The most common payment nature is "" ($5,000).
Ad
Practice Information
- Specialty Otolaryngology
- Location Acworth, GA
- Active Since 12/27/2006
- Last Updated 11/19/2011
- Taxonomy Code 207Y00000X
- Entity Type Individual
- NPI Number 1457416570
Products in Payments
- NUCALA (Biological) $3,754
- FEVIPIPRANT (Drug) $12.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.